- Home
- WGRX vs MGNX Comparison
WGRX vs MGNX Comparison
Compare WGRX & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- MGNX
- Stock Information
- Founded
- WGRX 2022
- MGNX 2000
- Country
- WGRX United States
- MGNX United States
- Employees
- WGRX N/A
- MGNX N/A
- Industry
- WGRX Other Pharmaceuticals
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- MGNX Health Care
- Exchange
- WGRX Nasdaq
- MGNX Nasdaq
- Market Cap
- WGRX 111.0M
- MGNX 99.7M
- IPO Year
- WGRX 2025
- MGNX 2013
- Fundamental
- Price
- WGRX $1.50
- MGNX $1.59
- Analyst Decision
- WGRX
- MGNX Hold
- Analyst Count
- WGRX 0
- MGNX 5
- Target Price
- WGRX N/A
- MGNX $3.25
- AVG Volume (30 Days)
- WGRX 7.3M
- MGNX 960.4K
- Earning Date
- WGRX 11-11-2025
- MGNX 11-04-2025
- Dividend Yield
- WGRX N/A
- MGNX N/A
- EPS Growth
- WGRX N/A
- MGNX N/A
- EPS
- WGRX N/A
- MGNX N/A
- Revenue
- WGRX $36,738,599.00
- MGNX $165,495,000.00
- Revenue This Year
- WGRX N/A
- MGNX N/A
- Revenue Next Year
- WGRX N/A
- MGNX N/A
- P/E Ratio
- WGRX N/A
- MGNX N/A
- Revenue Growth
- WGRX 82384.51
- MGNX 303.47
- 52 Week Low
- WGRX $0.62
- MGNX $0.99
- 52 Week High
- WGRX $7.04
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- MGNX 45.01
- Support Level
- WGRX N/A
- MGNX $1.68
- Resistance Level
- WGRX N/A
- MGNX $1.77
- Average True Range (ATR)
- WGRX 0.00
- MGNX 0.16
- MACD
- WGRX 0.00
- MGNX -0.02
- Stochastic Oscillator
- WGRX 0.00
- MGNX 3.08
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. It is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.